BioTuesdays

Category - Developments

BioLight Life Sciences Ltd.
Developments

BioLight posts positive latanoprost insert data

BioLight Life Sciences (TASE:BOLT) announced successful results from its glaucoma insert, VS101, (Eye-D latanoprost) in a Phase 1/2a clinical trial, which demonstrated its ability to lower intraocular pressure (IOP) for...

July 24, 2017
Theratechnologies
Developments

Theratechnologies presents new HIV findings

Theratechnologies’ (TSX:TH) presented results on HIV susceptibility to ibalizumab from a Phase 2b trial, along with new findings for EGRIFTA (tesamorelin for injection), at the 9th IAS Conference on HIV Science in Paris...

July 24, 2017
Developments

Dimerix posts positive Phase 2a in CKD

Dimerix (ASX:DXB) announced positive safety and efficacy data following a 27-patient Phase 2a proof-of-concept, dose escalation study in chronic kidney disease (CKD) for lead program, DMX-200. Dimerix will now progress...

July 12, 2017
Scientus Pharma Logo
Developments

Scientus inks cannabis supply pact with Aphria

Closely-held Scientus Pharma, through its HydRx Farms unit, has entered into a major wholesale purchase agreement with Aphria (TSX:APH; OTCQB:APHQF). Under the accord, Aphria would supply more than 25,000 fully-grown...

July 4, 2017
Titan Pharmaceuticals Logo
Developments

Fortune hails Titan’s ProNeura technology

Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.” The article said Titan’s Probuphine implant for the treatment of...

June 28, 2017
Developments

Stryker to acquire Novadaq Technologies

Stryker (NYSE:SYK) has agreed to acquire Novadaq Technologies (NASDAQ:NVDQ; TSX:NDQ) for $11.75 a share, implying a total equity value of approximately $701-million. The transaction price represents a premium of...

June 19, 2017